

Omrix Biopharmaceuticals, Inc.  
Form SC TO-T  
November 25, 2008

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE TO**

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)**  
**of the Securities Exchange Act of 1934**

**OMRIX BIOPHARMACEUTICALS, INC.**  
*(Name of Subject Company (Issuer))*

**BINDER MERGER SUB, INC.**  
*(Offeror)*  
*A Wholly-Owned Subsidiary of*

**JOHNSON & JOHNSON**  
*(Parent of Offeror)*  
*(Names of Filing Persons (identifying status as offeror, issuer or other person))*

**COMMON STOCK, \$0.01 PAR VALUE**  
*(Title of Class of Securities)*

**681989109**  
*(CUSIP Number of Class of Securities)*

**James J. Bergin, Esq.**  
**Johnson & Johnson**  
**One Johnson & Johnson Plaza**  
**New Brunswick, NJ 08933**  
**(732) 524-0900**

*(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)*

*Copies to:*

**Robert I. Townsend, III**  
**Eric L. Schiele**  
**Cravath, Swaine & Moore LLP**  
**Worldwide Plaza**  
**825 Eighth Avenue**  
**New York, NY 10019-7475**  
**(212) 474-1000**

**CALCULATION OF FILING FEE**

**Transaction Valuation(1)**

**Amount of Filing Fee(2)**

**\$447,192,900**

**\$17,574.69**

- (1) Estimated for purposes of calculating the filing fee only. This amount is determined by multiplying 17,887,716 shares of Omrix Biopharmaceuticals, Inc. common stock (representing the number of shares, including shares of common stock outstanding, in-the-money options, warrants and restricted stock units) by \$25.00 per share, which is the offer price.
- (2) The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934 and Fee Rate Advisory #6 for fiscal year 2008, issued December 27, 2007, by multiplying the transaction value by .0000393.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Amount Previously Paid: N/A  
Form of Registration No.: N/A

Filing Party: N/A  
Date Filed: N/A

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- Third-party tender offer subject to Rule 14d-1.  
 Issuer tender offer subject to Rule 13e-4.  
 Going-private transaction subject to Rule 13e-3.  
 Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.

---

This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this Schedule TO ) is filed by (i) Binder Merger Sub, Inc., a Delaware corporation (the Purchaser ) and wholly-owned subsidiary of Johnson & Johnson, a New Jersey corporation ( Parent ), and (ii) Parent. This Schedule TO relates to the offer by the Purchaser to purchase all of the outstanding shares of common stock, par value \$0.01 per share (the Shares ), of Omrix Biopharmaceuticals, Inc., a Delaware corporation (the Company ), at a purchase price of \$25.00 per Share net to the seller in cash without interest thereon, less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 25, 2008 (together with any amendments and supplements thereto, the Offer to Purchase ) and in the related Letter of Transmittal, copies of which are attached hereto as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

**Item 1. Summary Term Sheet.**

The information set forth in the section of the Offer to Purchase entitled Summary Term Sheet is incorporated herein by reference.

**Item 2. Subject Company Information.**

(a) The name of the subject company and the issuer of the securities to which this Schedule TO relates is Omrix Biopharmaceuticals, Inc., a Delaware corporation. The Company's principal executive offices are located at 1120 Avenue of the Americas, New York, NY 10036. The Company's telephone number at such address is (212) 887-6500.

(b) This Schedule TO relates to the outstanding shares of common stock, par value \$0.01 per share, of the Company. The Company has advised Parent that, as of November 20, 2008, 17,130,332 Shares were issued and outstanding, 1,090,909 Shares were reserved for issuance under the Company's equity plans (including 942,475 reserved for issuance pursuant to outstanding stock options and 94,779 reserved for issuance pursuant to outstanding restricted stock and RSUs) and 38,903 Shares were reserved for issuance upon the exercise of outstanding warrants.

(c) The information set forth in the section in the Offer to Purchase entitled Price Range of Shares; Dividends is incorporated herein by reference.

**Item 3. Identity and Background of Filing Person.**

(a) through (c) This Schedule TO is filed by Parent and the Purchaser. The information set forth in the section of the Offer to Purchase entitled Certain Information Concerning Parent and the Purchaser and in Schedule I to the Offer to Purchase is incorporated herein by reference.

**Item 4. Terms of the Transaction.**

The information set forth in the Offer to Purchase is incorporated herein by reference.

**Item 5. Past Contacts, Transactions, Negotiations and Agreements.**

The information set forth in the sections of the Offer to Purchase entitled Summary Term Sheet, Introduction, Certain Information Concerning Parent and the Purchaser, Background of the Offer; Past Contacts or Negotiations with Seller, Purpose of the Offer; Plans for Seller and The Transaction Agreements is incorporated herein by reference.

**Item 6. Purposes of the Transaction and Plans or Proposals.**

The information set forth in the sections of the Offer to Purchase entitled Summary Term Sheet, Introduction, Price Range of Shares; Dividends, Certain Effects of the Offer, Purpose of the Offer; Plans for Seller and The Transaction Agreements is incorporated herein by reference.

**Item 7. *Source and Amount of Funds or Other Consideration.***

The information set forth in the section of the Offer to Purchase entitled Source and Amount of Funds is incorporated herein by reference.

---

**Item 8. *Interest in Securities of the Subject Company.***

The information set forth in the sections of the Offer to Purchase entitled *Certain Information Concerning Parent and the Purchaser*, *Purpose of the Offer; Plans for Seller* and *The Transaction Agreements* is incorporated herein by reference.

**Item 9. *Persons/Assets Retained, Employed, Compensated or Used.***

The information set forth in the section of the Offer to Purchase entitled *Fees and Expenses* is incorporated herein by reference.

**Item 10. *Financial Statements.***

Not applicable.

**Item 11. *Additional Information.***

(a)(1) The information set forth in the sections of the Offer to Purchase entitled *Certain Information Concerning Parent and the Purchaser*, *Background of the Offer; Past Contacts or Negotiations with Seller*, *Purpose of the Offer; Plans for Seller* and *The Transaction Agreements* is incorporated herein by reference.

(a)(2) The information set forth in the sections of the Offer to Purchase entitled *Purpose of the Offer; Plans for Seller*, *Certain Conditions of the Offer* and *Certain Legal Matters; Regulatory Approvals* is incorporated herein by reference.

(a)(3) The information set forth in the sections of the Offer to Purchase entitled *Certain Conditions of the Offer* and *Certain Legal Matters; Regulatory Approvals* is incorporated herein by reference.

(a)(4) The information set forth in the sections of the Offer to Purchase entitled *Certain Effects of the Offer*, *Source and Amount of Funds* and *Certain Legal Matters; Regulatory Approvals* is incorporated herein by reference.

(a)(5) None.

(b) The information set forth in the Offer to Purchase is incorporated herein by reference.

**Item 12. Exhibits.**

| <b>Exhibit</b> | <b>Exhibit Name</b>   |
|----------------|---|
| (a)(1)(A)      | Offer to Purchase dated November 25, 2008.  |
| (a)(1)(B)      | Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number (TIN) on Substitute Form W-9 and Tax Declaration).  |
| (a)(1)(C)      | Notice of Guaranteed Delivery.  |
| (a)(1)(D)      | Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.   |
| (a)(1)(E)      | Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.  |
| (a)(5)(A)      | Joint Press Release issued by Johnson & Johnson and Omrix Biopharmaceuticals, Inc. on November 24, 2008, incorporated herein by reference to Exhibit 99.1 to the Schedule TO filed by Johnson & Johnson on November 24, 2008. |
| (a)(5)(B)      | Summary Newspaper Advertisement as published in The Wall Street Journal on November 25, 2008.   |
| (a)(5)(C)      | Press Release issued by Johnson & Johnson on November 25, 2008.   |
| (b)            | Not applicable.   |
| (d)(1)         | Agreement and Plan of Merger, dated as of November 23, 2008, by and among Johnson & Johnson, Binder Merger Sub, Inc. and Omrix Biopharmaceuticals, Inc.   |
| (d)(2)         | Tender and Support Agreement, dated as of November 23, 2008, by and among Johnson & Johnson, Binder Merger Sub, Inc. and the stockholders of Omrix Biopharmaceuticals, Inc. listed on Schedule I thereto.                     |
| (d)(3)         | Letter Agreement, dated as of November 21, 2008, by and among Omrix Biopharmaceuticals, Inc., Johnson & Johnson, and Robert Taub, amending the Taub Employment Agreement dated March 20, 2006.                                |
| (d)(4)         | Retention Agreement, dated as of November 20, 2008, by and among Omrix Biopharmaceuticals, Inc., Johnson & Johnson, and Nissim Mashiach.  |
| (g)            | Not applicable.   |
| (h)            | Not applicable.   |

**Item 13. Information Required by Schedule 13E-3.**

Not applicable.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BINDER MERGER SUB, INC.

By /s/ James J. Bergin

Name: James J. Bergin

Title: Vice President

Date: November 25, 2008

JOHNSON & JOHNSON

By /s/ John A. Papa

Name: John A. Papa

Title: Treasurer

Date: November 25, 2008

| <b>Exhibit</b> | <b>Exhibit Name</b>   |
|----------------|---|
| (a)(1)(A)      | Offer to Purchase dated November 25, 2008.  |
| (a)(1)(B)      | Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number (TIN) on Substitute Form W-9 and Tax Declaration).  |
| (a)(1)(C)      | Notice of Guaranteed Delivery.  |
| (a)(1)(D)      | Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.   |
| (a)(1)(E)      | Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.  |
| (a)(5)(A)      | Joint Press Release issued by Johnson & Johnson and Omrix Biopharmaceuticals, Inc. on November 24, 2008, incorporated herein by reference to Exhibit 99.1 to the Schedule TO filed by Johnson & Johnson on November 24, 2008. |
| (a)(5)(B)      | Summary Newspaper Advertisement as published in The Wall Street Journal on November 25, 2008.   |
| (a)(5)(C)      | Press Release issued by Johnson & Johnson on November 25, 2008.   |
| (b)            | Not applicable.   |
| (d)(1)         | Agreement and Plan of Merger, dated as of November 23, 2008, by and among Johnson & Johnson, Binder Merger Sub, Inc. and Omrix Biopharmaceuticals, Inc.   |
| (d)(2)         | Tender and Support Agreement, dated as of November 23, 2008, by and among Johnson & Johnson, Binder Merger Sub, Inc. and the stockholders of Omrix Biopharmaceuticals, Inc. listed on Schedule I thereto.                     |
| (d)(3)         | Letter Agreement, dated as of November 21, 2008, by and among Omrix Biopharmaceuticals, Inc., Johnson & Johnson, and Robert Taub, amending the Taub Employment Agreement dated March 20, 2006.                                |
| (d)(4)         | Retention Agreement, dated as of November 20, 2008, by and among Omrix Biopharmaceuticals, Inc., Johnson & Johnson, and Nissim Mashiach.  |
| (g)            | Not applicable.   |
| (h)            | Not applicable.   |